PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 11249123-4 2001 We designed non-peptidic inhibitors based on the predicted binding mode of the peptidic chymase inhibitor Val-Pro-Phe-CF3 and demonstrated that the Val-Pro unit is replaceable with a (5-amino-6-oxo-2-phenyl-1,6-dihydro-1-pyrimidinyl)acetyl moiety. L-valyl-L-proline 106-113 chymase 1 Homo sapiens 88-95 11916317-9 2001 The characteristic resonances in the urine from a prolidase-deficient patient, i.e. Ala-Pro, Val-Pro, Gly-Pro, and resonances of the (hydroxy)proline part of the imidodipeptides can be used to diagnose this disease. L-valyl-L-proline 93-100 peptidase D Homo sapiens 50-59 18550075-2 2008 The different effects of reaction conditions including the concentration of Mn(2+), incubation temperature and pH on prolidase (PLD, EC 3.4.13.9) activity in erythrocyte lysates against three different substrates, Gly-Pro, Val-Pro and Leu-Pro were investigated. L-valyl-L-proline 223-230 peptidase D Homo sapiens 117-126 18550075-2 2008 The different effects of reaction conditions including the concentration of Mn(2+), incubation temperature and pH on prolidase (PLD, EC 3.4.13.9) activity in erythrocyte lysates against three different substrates, Gly-Pro, Val-Pro and Leu-Pro were investigated. L-valyl-L-proline 223-230 peptidase D Homo sapiens 128-131 32970728-7 2020 Additionally, the V-P complex significantly up-regulated the protein levels of total beta-catenin (t-beta-catenin), nuclear beta-catenin (n-beta-catenin), phosphorylated adenosine monophosphate-activated protein kinase alpha (p-AMPKalpha) and liver kinase B1 (p-LKB1). L-valyl-L-proline 18-21 catenin beta 1 Homo sapiens 101-113 6478829-2 1984 The method is based on the separation of the alkaline hydrolysis-resistant dipeptide valyl-proline, a dipeptide found in high concentrations in elastin. L-valyl-L-proline 85-98 elastin Homo sapiens 144-151 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 peroxisome proliferator activated receptor gamma Homo sapiens 184-232 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 peroxisome proliferator activated receptor gamma Homo sapiens 234-243 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 CCAAT enhancer binding protein alpha Homo sapiens 246-282 2964043-4 1987 Furthermore, direct estimation of the number of val-pro sequence in different elastin preparations indicated a drop from 49.3 to 29.2 per 1,000 residues in normotensive controls and preparations obtained from spontaneously hypertensive rats respectively. L-valyl-L-proline 48-55 elastin Rattus norvegicus 78-85 4004871-3 1985 On the other hand elastin and tropoelastin preparations obtained from SHR rats show a lower frequency of the Val-Pro sequence; this was found to be 35.93 per 1000 amino acid residues in SHR rats as compared to 51.04 per 1000 amino acids in the preparations obtained from control animals. L-valyl-L-proline 109-116 elastin Rattus norvegicus 18-25 4004871-3 1985 On the other hand elastin and tropoelastin preparations obtained from SHR rats show a lower frequency of the Val-Pro sequence; this was found to be 35.93 per 1000 amino acid residues in SHR rats as compared to 51.04 per 1000 amino acids in the preparations obtained from control animals. L-valyl-L-proline 109-116 elastin Rattus norvegicus 30-42 6955938-6 1981 The results of this study suggest that V-P therapy is more effective for CML blast crisis in childhood with TdT positive blast cells and that prophylactic central nervous system treatment is necessary to prevent meningeal leukaemia. L-valyl-L-proline 39-42 DNA nucleotidylexotransferase Homo sapiens 108-111 426288-0 1979 Valyl-proline as an index of elastin biosynthesis. L-valyl-L-proline 0-13 elastin Homo sapiens 29-36 32970728-7 2020 Additionally, the V-P complex significantly up-regulated the protein levels of total beta-catenin (t-beta-catenin), nuclear beta-catenin (n-beta-catenin), phosphorylated adenosine monophosphate-activated protein kinase alpha (p-AMPKalpha) and liver kinase B1 (p-LKB1). L-valyl-L-proline 18-21 catenin beta 1 Homo sapiens 101-113 32970728-7 2020 Additionally, the V-P complex significantly up-regulated the protein levels of total beta-catenin (t-beta-catenin), nuclear beta-catenin (n-beta-catenin), phosphorylated adenosine monophosphate-activated protein kinase alpha (p-AMPKalpha) and liver kinase B1 (p-LKB1). L-valyl-L-proline 18-21 serine/threonine kinase 11 Homo sapiens 243-258 32970728-7 2020 Additionally, the V-P complex significantly up-regulated the protein levels of total beta-catenin (t-beta-catenin), nuclear beta-catenin (n-beta-catenin), phosphorylated adenosine monophosphate-activated protein kinase alpha (p-AMPKalpha) and liver kinase B1 (p-LKB1). L-valyl-L-proline 18-21 serine/threonine kinase 11 Homo sapiens 262-266 32970728-8 2020 These showed that the inhibitory effect of V-P complex on human adipogenesis was mediated by activating Wnt/beta-catenin and LKB1/AMPK-dependent signaling pathway. L-valyl-L-proline 43-46 catenin beta 1 Homo sapiens 108-120 32970728-8 2020 These showed that the inhibitory effect of V-P complex on human adipogenesis was mediated by activating Wnt/beta-catenin and LKB1/AMPK-dependent signaling pathway. L-valyl-L-proline 43-46 serine/threonine kinase 11 Homo sapiens 125-129 32970728-8 2020 These showed that the inhibitory effect of V-P complex on human adipogenesis was mediated by activating Wnt/beta-catenin and LKB1/AMPK-dependent signaling pathway. L-valyl-L-proline 43-46 protein kinase AMP-activated catalytic subunit alpha 2 Homo sapiens 130-134 31304983-2 2019 Here, we analyze why many COP1-interacting transcription factors and photoreceptors harbor sequence-divergent Val-Pro (VP) motifs that bind COP1 with different binding affinities. L-valyl-L-proline 110-117 COP1 E3 ubiquitin ligase Homo sapiens 26-30 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 CCAAT enhancer binding protein alpha Homo sapiens 284-294 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 sterol regulatory element binding transcription factor 1 Homo sapiens 297-340 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 sterol regulatory element binding transcription factor 1 Homo sapiens 342-349 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 fatty acid synthase Homo sapiens 355-374 32970728-6 2020 In this study, the 20 mug/mL of V-P complex reduced the lipid and triglyceride (TG) content by 74.47 and 57.39% (p < 0.05), respectively, and down-regulated the protein expressions of peroxisome proliferator-activated receptor-gamma (PPARgamma), CCAAT/enhancer-binding protein alpha (C/EBPalpha), sterol regulatory element-binding protein 1 (SREBP-1) and fatty acid synthase (FAS). L-valyl-L-proline 32-35 fatty acid synthase Homo sapiens 376-379 32970728-7 2020 Additionally, the V-P complex significantly up-regulated the protein levels of total beta-catenin (t-beta-catenin), nuclear beta-catenin (n-beta-catenin), phosphorylated adenosine monophosphate-activated protein kinase alpha (p-AMPKalpha) and liver kinase B1 (p-LKB1). L-valyl-L-proline 18-21 catenin beta 1 Homo sapiens 85-97 32970728-7 2020 Additionally, the V-P complex significantly up-regulated the protein levels of total beta-catenin (t-beta-catenin), nuclear beta-catenin (n-beta-catenin), phosphorylated adenosine monophosphate-activated protein kinase alpha (p-AMPKalpha) and liver kinase B1 (p-LKB1). L-valyl-L-proline 18-21 catenin beta 1 Homo sapiens 101-113 31304983-2 2019 Here, we analyze why many COP1-interacting transcription factors and photoreceptors harbor sequence-divergent Val-Pro (VP) motifs that bind COP1 with different binding affinities. L-valyl-L-proline 110-117 COP1 E3 ubiquitin ligase Homo sapiens 140-144 31151077-6 2019 cis-Cyclo(Val-Pro) (2) exhibited 57% inhibition of plasma IL-1beta protein expression and 35.2% inhibition of elevated blood urea nitrogen. L-valyl-L-proline 10-17 interleukin 1 beta Mus musculus 58-66 31151077-7 2019 Further, cis-cyclo(Val-Pro) (2) attenuated renal injury as demonstrated by significant reduction of mRNA expressions of IL-1beta (P < 0.01) and kidney injury marker-1 (P < 0.001). L-valyl-L-proline 19-26 interleukin 1 beta Mus musculus 120-128